Opaleye Management Inc. Makes New Investment in Replimune Group, Inc. $REPL

Opaleye Management Inc. acquired a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,384,993 shares of the company’s stock, valued at approximately $15,332,000. Replimune Group comprises about 1.4% of Opaleye Management Inc.’s investment portfolio, making the stock its 20th biggest position.

Other hedge funds and other institutional investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares during the last quarter. Millennium Management LLC boosted its stake in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after buying an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after buying an additional 119,145 shares during the last quarter. Rhumbline Advisers grew its holdings in Replimune Group by 6.9% in the 2nd quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after buying an additional 6,616 shares during the period. Finally, Sei Investments Co. grew its holdings in Replimune Group by 149.5% in the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after buying an additional 18,263 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on REPL. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research note on Tuesday, June 30th. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th. Finally, Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Replimune Group Price Performance

Replimune Group stock opened at $13.24 on Friday. The firm has a fifty day moving average of $12.50 and a 200-day moving average of $8.79. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $16.33. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.24 billion, a P/E ratio of -4.20 and a beta of 0.94.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, analysts predict that Replimune Group, Inc. will post -2.81 EPS for the current year.

Insider Buying and Selling

In other news, CFO Emily Hill sold 11,448 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,480.56. Following the completion of the sale, the chief financial officer owned 225,108 shares of the company’s stock, valued at $2,919,650.76. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the sale, the insider owned 224,215 shares of the company’s stock, valued at approximately $2,908,068.55. This trade represents a 4.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 79,124 shares of company stock valued at $1,038,364. 5.40% of the stock is owned by company insiders.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.